Big pharma’s billion-dollar bets

As patents lapse and investors exert pressure to cut R&D spending, large drug companies are investing big money in risky takeovers to fund their next blockbuster drug. The FT's Arash Massoudi explains that more deals may follow a big year of dealmaking